UK regulator advises stopping reimbursement for Amgen's lung cancer drug Lumakras for new patients

The National Institute for Health and Care Excellence (NICE) in the United Kingdom released draft guidance recommending that government reimbursement for Amgen’s lung cancer therapy Lumakras be discontinued for patients who have not yet started treatment.

The recommendation targets new patients, meaning those who would begin Lumakras therapy after the guidance takes effect would no longer be eligible for NHS funding. Existing patients already receiving the drug are not mentioned as being affected.

NICE’s move reflects concerns about the drug’s cost‑effectiveness in the NHS setting, although the article does not provide specific data on pricing or clinical outcomes.

The decision could impact Amgen’s revenue expectations in the UK market and may prompt the company to seek further negotiations or present additional evidence to support the drug’s value.